GlassScriptPhysician profile
Mitchell C Handrich
NPI 1861850034
$5,118.41
in general payments reported to CMS, 2019-2025
18 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $909 · 2023: $482 · 2024: $2,473 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Consulting Fee: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.20 |
| Consulting Fee | $1,860.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,009.55 | 2021-2025 | Yeztugo, Biktarvy |
| Viiv Healthcare Company | $1,132.78 | 2022-2025 | Apretude, Dovato, Rukobia |
| Merck Sharp & Dohme LLC | $168.93 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $117.03 | 2025 | Egrifta, Trogarzo |
| Janssen Products, LP | $99.99 | 2021 | |
| Mannkind Corporation | $84.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.02 | 2025 | Invega |
| Exact Sciences Corporation | $69.83 | 2025 | The Cologuard Plus Collection Kit |
| Alkermes, INC. | $68.39 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Braeburn INC. | $63.82 | 2024-2025 | Brixadi |
| Janssen Biotech, INC. | $49.54 | 2021-2023 | Symtuza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.75 | 2025 | Caplyta |
| Lilly USA, LLC | $31.31 | 2024-2025 | Mounjaro, Zepbound |
| Indivior INC. | $26.75 | 2024 | Perseris |
| Organon LLC | $22.57 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.45 | 2025 | |
| Genzyme Corporation | $18.11 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Handrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.